NBY - NovaBay Pharmaceuticals Inc. Price-to-Revenue Ratio

Symbol and logo of brand novabay.com (NBY)

The historical P/S on the current GURU.Markets platform chart recorded a value of 18.50. NovaBay Pharmaceuticals (NBY) sales dynamics are complicated by severe pricing pressure in the over-the-counter segment. However, the company is developing niche potential by creating safe Avenova antimicrobial formulas. Automated assembly lines of contract partners, operating on a strict schedule, ensure the stability of product output.

P/S Multiple: NovaBay Pharmaceuticals, Inc. (NBY) for 07/04/2022 - 04/18/2026

NovaBay Pharmaceuticals (NBY) - metric breakdowns and financial figures

- current quotes and average value forecast:
Summary company analytics:NovaBay Pharmaceuticals, NBY
Signature product of NovaBay

The P/S ratio compares the market capitalization of NovaBay Pharmaceuticals (NBY) to its annual sales volume, determining the cost of one dollar of revenue. By analyzing the price-to-sales metric, an investor assesses the extent of the premium paid for the business relative to its actual cash flows. A decline in this metric may signal that the asset is undervalued. This is critical for NovaBay Pharmaceuticals (NBY), as intense generic pressure and marketing expenses limit margin growth.